Brainstorm Cell TherapeuticsBCLI
13F holders, Q2 2024 (June 30)48holders +1
6new positions
6sold out
$0.33avg. 13F price*
At the end of Q2 2024, 48 institutions reported holding Brainstorm Cell Therapeutics (BCLI) in their 13F filings, up 1 from Q1 2024. 6 opened new positions and 6 sold out. The largest holders were Armistice Capital, LLC ($2.7M), Vanguard Group Inc. ($511K) and Geode Capital Management, LLC ($164K).
- Company
- Brainstorm Cell Therapeutics
- CUSIP
- 10501E201
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $2.7M |
| Exits | 6 | $136K |
All 13F filers, Q1 2024 → Q2 2024: 8,536,913 shares bought and 362,901 shares sold, net +8,174,012 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 48 holders
| Armistice Capital, LLC | 0.07% | New | 7,917,653 | $2.7M |
| Vanguard Group Inc. | 0.00% | Add +7.8% | 1,510,640 | $511K |
| Geode Capital Management, LLC | 0.00% | Add +35.6% | 484,285 | $164K |
| BlackRock Inc. | 0.00% | Reduce -21.0% | 386,414 | $131K |
| Liberty Wealth Management LLC | 0.02% | No change | 340,150 | $115K |
| Weaver Consulting Group | 0.03% | Add +17.6% | 234,356 | $79K |
| Abner Herrman & Brock LLC | 0.01% | No change | 145,500 | $49K |
| State Street Corp. | 0.00% | Add +22.1% | 117,260 | $40K |
| Northern Trust Corp. | 0.00% | Add +105.1% | 112,358 | $38K |
| Raymond James & Associates | 0.00% | Reduce -2.2% | 111,285 | $38K |
| Two Sigma Securities, LLC | 0.00% | New | 102,016 | $35K |
| Ikarian Capital, LLC | 0.01% | No change | 90,242 | $31K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +686.7% | 86,579 | $29K |
| Jmac Enterprises LLC | 0.00% | No change | 65,430 | $22K |
| Virtu Financial LLC | 0.00% | New | 49,586 | $17K |
| Group One Trading LLC | 0.00% | Add +52.5% | 46,754 | $16K |
| Morgan Stanley | 0.00% | Reduce -7.8% | 36,975 | $13K |
| Wells Fargo & Company | 0.00% | Reduce -1.0% | 28,811 | $10K |
| Sanctuary Advisors, LLC | 0.00% | — | 17,210 | $9K |
| Creative Planning | 0.00% | Reduce -3.7% | 20,926 | $7K |
| Janney Montgomery Scott LLC | 0.00% | No change | 20,500 | $7K |
| Jane Street Group, LLC | 0.00% | Add +5.9% | 19,834 | $7K |
| Professional Financial Advisors, LLC | 0.00% | No change | 17,279 | $6K |
| First Affirmative Financial Network | 0.00% | Reduce -6.5% | 14,293 | $5K |
| Saxony Capital Management, LLC | 0.00% | Reduce -38.2% | 12,950 | $4K |
| Bank of New York Mellon Corp | 0.00% | No change | 11,994 | $4K |
| Avior Wealth Management, LLC | 0.00% | Reduce -11.5% | 11,232 | $4K |
| Osaic Holdings, Inc. | 0.00% | No change | 10,519 | $4K |
| LPL Financial LLC | 0.00% | New | 10,052 | $3K |
| UBS Group AG | 0.00% | Add +184.4% | 7,110 | $2K |
| Activest Wealth Management | 0.00% | New | 7,080 | $2K |
| Institutional & Family Asset Management, LLC | 0.00% | No change | 6,000 | $2K |
| Bangor Savings Bank | 0.00% | No change | 4,000 | $1K |
| Simplex Trading, LLC | 0.00% | Add +36.3% | 5,504 | $1K |
| Steward Partners Investment Advisory, LLC | 0.00% | Reduce -35.7% | 2,700 | $914 |
| EverSource Wealth Advisors, LLC | 0.00% | No change | 2,128 | $728 |
| Balefire, LLC | 0.00% | No change | 1,944 | $658 |
| Clearstead Advisors, LLC | 0.00% | No change | 1,500 | $508 |
| Bank of America Corp. | 0.00% | Add +49.2% | 1,492 | $504 |
| Cranbrook Wealth Management, LLC | 0.00% | No change | 1,000 | $339 |
| St Germain D J Co. Inc. | 0.00% | No change | 500 | $169 |
| BNP Paribas Financial Markets | 0.00% | No change | 364 | $123 |
| JPMorgan Chase & Co. | 0.00% | Add +140.6% | 255 | $86 |
| Westside Investment Management, Inc. | 0.00% | No change | 200 | $68 |
| Northwestern Mutual Wealth Management Co. | 0.00% | New | 161 | $55 |
| Mark Sheptoff Financial Planning, LLC | 0.00% | No change | 100 | $34 |
| Caldwell Sutter Capital, Inc. | 0.00% | No change | 157,009 | $0 |
| Royal Bank of Canada | 0.00% | Add +66.9% | 529 | $0 |
"% of holder's portfolio" is BCLI's weight in each manager's 13F, not the share of Brainstorm Cell Therapeutics the manager owns.